Duality Advisers LP Raises Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Duality Advisers LP boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 35.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,641 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,758 shares during the quarter. Duality Advisers LP’s holdings in Jazz Pharmaceuticals were worth $3,154,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of JAZZ. Daiwa Securities Group Inc. grew its stake in Jazz Pharmaceuticals by 2.5% during the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock worth $528,000 after buying an additional 100 shares during the period. Waterfront Wealth Inc. grew its stake in Jazz Pharmaceuticals by 1.2% during the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock worth $1,062,000 after buying an additional 103 shares during the period. Prime Capital Investment Advisors LLC grew its stake in Jazz Pharmaceuticals by 4.3% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock worth $325,000 after buying an additional 108 shares during the period. Johnson Investment Counsel Inc. grew its stake in Jazz Pharmaceuticals by 0.8% during the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock worth $1,695,000 after buying an additional 110 shares during the period. Finally, Fifth Third Bancorp grew its stake in Jazz Pharmaceuticals by 2.2% during the third quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company’s stock worth $691,000 after buying an additional 114 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JAZZ has been the topic of a number of recent research reports. Truist Financial reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. UBS Group reduced their target price on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, March 22nd. Finally, Barclays reduced their target price on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $0.03 on Monday, reaching $109.97. 116,661 shares of the company’s stock were exchanged, compared to its average volume of 608,681. The firm has a market capitalization of $6.93 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 1.52 and a beta of 0.59. Jazz Pharmaceuticals plc has a fifty-two week low of $106.61 and a fifty-two week high of $146.70. The business’s 50-day moving average is $119.81 and its two-hundred day moving average is $122.41. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction dated Friday, March 1st. The stock was acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares of the company’s stock, valued at $3,342,063.80. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.